Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Fluoxetine indications

Antidepressants. Short-term studies of desipramine and fluoxetine indicate that both medications reduce binging in patients with BED. In addition, fluoxetine-treated patients may also experience a modest reduction in weight during short-term treatment. However, this early weight loss with fluoxetine may not be sustained despite continued treatment. [Pg.226]

There are few controlled clinical trials of drugs in children and adolescents with GAD. CBT alone or in conjunction with antidepressants can have long-term benefits. Randomized controlled trials of sertraline and fluovoxamine, and open trials of alprazolam, clonazepam, and fluoxetine indicate short-term efficacy however, be-... [Pg.1291]

The eudismic ratio of the R- and S isomer for the inhibition of %-paroxetine is one, so their potencies are the same. However, the selectivity index for the inhibition of H-paroxetine and %[-tomoxetine binding is 24 for the R isomer and 155 for the S isomer of fluoxetine indicating that the R isomer is less selective than the S isomer in regard to the afflnily of the compounds for the 5-HT tremsporter versus the NE transporter. [Pg.342]

NOTE The inhibitor (5 m kg) was administered at the indicated times after MDMA, and all animals were sacrificed 7 days later. Data are presented as a percentage of the appropriate control (saline or fluoxetine alone), mean SEM. [Pg.192]

Sumatriptan is a 5HT (serotonin) agonist indicated in the treatment of migraine. Sumatriptan causes vasoconstriction and must therefore be used with caution in patients with coronary heart disease, such as angina. Concurrent administration of the agonist, sumatriptan and antagonists, such as fluoxetine, which is a selective serotonin re-uptake inhibitor, leads to increased CNS toxicity. [Pg.120]

Administer once daily in the evening, generally beginning with the 6 mg/25 mg capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of olanzapine/fluoxetine has not been studied. Dosage adjustments, if indicated, can be made according to efficacy and tolerability. Antidepressant efficacy was demonstrated with olanzapine/fluoxetine in a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. The safety of doses above 18 mg/75 mg has not been... [Pg.1176]

Special populations Use a starting dose of 6 mg/25 mg for patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine/fluoxetine (eg, female gender, elderly, nonsmoking status). When indicated, perform dose escalation with caution in these patients. Olanzapine/fluoxetine has not been systemically studied in patients older than 65 years of age or in patients younger than 18 years of age. [Pg.1177]

The prototypical serotonin reuptake inhibitor (SRI) medication is the non-selective agent clomipramine, a tricyclic antidepressant (TCA). The Selective SRIs (SSRIs) include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox), and citalo-pram (Celexa). The Food and Drug Administration (FDA) approved clinical indications for these medications are described in Table 22.1. [Pg.274]

Sovner et al. (1998) have done an excellent job summarizing the data on antidepressants in patients with developmental disabilities. There have been nine reports of antidepressant use in adults with depression and MR and three reports of antidepressant use in children and adolescents. Eight of nine reports in adults were positive. The drugs studied included nialimide (n = 27), fluoxetine (9), imipramine (6), amoxapine (2), and nortriptyline (1) (total n = 45). In addition, Sovner et al. identified four reports of antidepressant use in children. One involved successful treatment with fluoxetine in an adolescent, another indicated efficacy with imipramine and amitriptyline in 9 of 12 children (Do-sen, 1982), and a third showed successful management in 3 of 4 children treated with imipramine or tryptophan plus nicotinamide (Dosen, 1990). One study of fluoxetine in depressed children with autism and MR witnessed improvement in depression but not in compulsive symptoms (Ghaziuddin and Tsai, 1991). [Pg.623]

In four instances, the agency has invoked this rule at the time of approval of supplements for new indications for psychotropic drugs already approved for other psychiatric indications. It was noted in the approval letters for these supplements that, since the drugs in question would likely be used in children and/ or adolescents with the newly approved indications, the FDA required the sponsors of these products to conduct studies that would be pertinent to such use in the pediatric population. Since the products were ready for approval in adults, the FDA deferred the required pediatric studies to a future date. Alternatively, sponsors could make an argument for waiver of the requirement. The drug products and indications for which the FDA has required studies under the Pediatric Rule are as follows paroxetine for social anxiety disorder sertraline for post-traumatic stress disorder (PTSD) olanzapine for acute mania in bipolar disorder and fluoxetine in premenstrual dysphoric disorder (PMDD). [Pg.731]

Some evidence indicates that social phobia responds to SSRls, and case reports and studies with fluoxetine [B. Black et al. 1992 Van Ameringen et al. 1993), fluvoxamine [Mendels et al. 1995), paroxetine [Pitts et al. 1996 Ringold 1994), and sertraline [Katzelnick et al. 1995) have reported positive results. Although the full details of these studies have not been published, it seems that SSRls might well prove, in due course, to be effective treatments for social phobia. At the moment, the only treatment licensed for social phobia is moclobemide, which is a reversible inhibitor of monoamine oxidase-A [Nutt and Montgomery 1996 Versiani et al. 1992), and it is possible that it... [Pg.204]

As other indications are sought for the SSRls, it is clear that their action extends beyond depression, dysthymia, and the anxiety disorders, and the broad spectrum of therapeutic action of these antidepressants becomes apparent. For example, based on the evidence from placebo-controlled studies [A. Wood 1993], fluoxetine has been licensed in Europe for the treatment of bulimia, and several SSRls are reported to be effective in the treatment of premenstrual syndrome. [Pg.205]

Basic pharmacology. Fluvoxamine is an effective serotonin reuptake inhibitor with an ICjg value of 0.3 pmol/L comparable ICjg values for desipramine and fluoxetine are 0.8 jmol/L and 1.3 omol/L, respectively [Bradford 1984]. The ICjo values for NA and dopamine were 100 times higher than those for serotonin [Bradford 1984]. In vitro data indicate that fluvoxamine has little or no affinity for Oj, a, Pi, P2, Dj, S-HTj, muscarinic, or histaminergic receptors [Benfield and Ward 1986]. Fluvoxamine has a total of 11 metabolites, and the 2 principal ones have little or no pharmacological activity [Claassen 1983]. [Pg.215]

Most antidepressants did not considerably change SWS. Nonetheless, evidence indicates that doxepine [Roth et al. 1982), imipramine (Kupfer et al. 1979), and fluoxetine [Kerkhofs et al. 1990) suppress SWS, whereas... [Pg.262]

The olanzapine-fluoxetine combination is currently the only medication approved by the FDA specifically for the treatment of depression in patients with bipolar disorder. This indication was based on data from a double-bhnd, randomized study in which the combination was superior to both olanzapine monotherapy and placebo (Tohen et al. 2003). Treatment-emergent mania or hypomania did not occur more frequently in the olanzapine-fluoxetine combination group than in the placebo group during the acute trial. [Pg.160]

A four-arm trial of fluoxetine in the treatment of OCD designed to compare 20. 40 and 60 mg/day of fluoxetine and placebo during a 13-week period. The results indicated greater efficacy of the 60mg/dav dose, suggesting that the optimal dose of fluoxetine is higher in the treatment of OCD than in depression (Tollefson et al., 1994). [Pg.192]

A three-arm trial during six menstrual cycles evaluating the efficacy and safety of fluoxetine treatment of premenstrual dysphoria. Both 20 and 60 mg/day were significantly more effective than placebo, without any salient benefit of the higher dose however, the women on 60mg/daj of fluoxetine reported significantly more side effects than those at the lower dose or placebo. Based on the results of this three-arm fixed-dose and similar trials, the recommended dose in this indication is 20 mg of fluoxetine (Steiner et ti/., 1995). [Pg.192]


See other pages where Fluoxetine indications is mentioned: [Pg.85]    [Pg.85]    [Pg.219]    [Pg.290]    [Pg.291]    [Pg.295]    [Pg.581]    [Pg.96]    [Pg.171]    [Pg.391]    [Pg.470]    [Pg.229]    [Pg.19]    [Pg.151]    [Pg.165]    [Pg.172]    [Pg.1084]    [Pg.387]    [Pg.303]    [Pg.500]    [Pg.515]    [Pg.515]    [Pg.520]    [Pg.537]    [Pg.587]    [Pg.626]    [Pg.643]    [Pg.730]    [Pg.202]    [Pg.209]    [Pg.296]    [Pg.542]    [Pg.10]    [Pg.23]   
See also in sourсe #XX -- [ Pg.274 , Pg.275 ]




SEARCH



Fluoxetin

Fluoxetine

© 2024 chempedia.info